The option of liver transplantation for hepatitis B: Where are we?

Digestive and Liver Disease

Volumn 41, Issue SUPPL. 2, 2009, Pages

  Samuel, D ^a,b,c  

^a Universite Paris Sud   (France)

^b UNIVERSITÉ PARIS SACLAY   (France)

^c HÔPITAL PAUL BROUSSE   (France)

Author keywords

Adefovir; HBV prophylaxis; Immunoglobulins; Lamivudine

Indexed keywords

ADEFOVIR; ANTIVIRUS AGENT; ENTECAVIR; HEPATITIS B ANTIBODY; HEPATITIS B VACCINE; IMMUNOSUPPRESSIVE AGENT; LAMIVUDINE; NUCLEOTIDE DERIVATIVE; TELBIVUDINE; TENOFOVIR; VIRUS DNA;

ANTIVIRAL THERAPY; ARTICLE; CHEMOPROPHYLAXIS; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG INDICATION; DRUG MEGADOSE; DRUG SAFETY; DRUG WITHDRAWAL; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; IMMUNOPROPHYLAXIS; INFECTION RISK; LIVER; LIVER TRANSPLANTATION; LONG TERM CARE; LOW DRUG DOSE; MONONUCLEAR CELL; PATIENT SELECTION; PRACTICE GUIDELINE; PRIORITY JOURNAL; RECURRENCE RISK; REINFECTION; RISK REDUCTION; SEROCONVERSION; VIRUS DETECTION; VIRUS LOAD; VIRUS MUTANT; VIRUS REPLICATION; VIRUS STRAIN;

ADENINE; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; HEPATITIS B; HUMANS; IMMUNOGLOBULINS; LAMIVUDINE; LIVER TRANSPLANTATION; PHOSPHONIC ACIDS; POSTOPERATIVE COMPLICATIONS; PRACTICE GUIDELINES AS TOPIC; RECURRENCE; VIRAL LOAD;

EID: 66149156965     PISSN: 15908658     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1590-8658(09)60442-4     Document Type: Article

References (26)

1. Samuel D., Muller R., Alexander G., Fassati L., Ducot B., Benhamou J.P., et al. Liver transplantation in European patients with the hepatitis B surface antigen. New Engl J Med 329 (1993) 1842-1847
2. Shouval D., and Samuel D. Hepatitis B immune globulin to prevent HBV graft reinfection following liver transplantation: a concise review. Hepatology 32 (2000) 1189-1195
3. Fontana R.J., Hann H.W., Perrillo R.P., Vierling J.M., Wright T., Rakela J., et al. Determinants of early mortality in patients with decompensated chronic hepatitis B treated with antiviral therapy. Gastroenterology 123 (2002) 719-727
4. Schiff E., Lai C.L., Hadziyannis S., Neuhaus P., Terrault N., Colombo M., et al. Adefovir dipivoxil for wait-listed and post-liver transplantation patients with lamivudine-resistant hepatitis B: final long-term results. Liver Transpl 13 (2007) 349-360
5. Steinmüller T., Seehofer D., Rayes N., Müller A.R., Settmacher U., Jonas S., et al. Increasing applicability of liver transplantation for patients with hepatitis B-related liver disease. Hepatology 35 (2002) 1528-1535
6. Terrault N., Roche B., and Samuel D. Management of the hepatitis B virus in the liver transplantation setting: a European and an American perspective. Liver Transpl 11 (2005) 716-732
7. Markowitz J.S., Martin P., Conrad A.J., Markmann J.F., Seu P., Yer-siz H., et al. Prophylaxis against hepatitis B recurrence following liver transplantation using combination lamivudine and hepatitis B immune globulin. Hepatology 28 (1998) 585-589
8. Rosenau J., Bahr M.J., Tillmann H.L., Trautwein C., Klempnauer J., Manns M.P., et al. Lamivudine and low-dose hepatitis B immune globulin for prophylaxis of hepatitis B reinfection after liver transplantation. Possible role of mutations in the YMDD motif prior to transplantation as a risk factor for reinfection. J Hepatol 34 (2001) 895-902
9. Gane E.J., Angus P.W., Strasser S., Crawford D.H., Ring J., Jeffrey G.P., et al. Lamivudine plus low-dose hepatitis B immune globulin to prevent recurrent hepatitis B following liver transplantation. Gastroenterology 132 (2007) 931-937
10. Perrillo R.P., Wright T., Rakela J., Levy G., Schiff E., Gish R., et al. A multicenter United States-Canadian trial to assess lamivudine monotherapy before and after transplantation for chronic hepatitis B. Hepatology 33 (2001) 424-432
11. Marzano A., Gaia S., Ghisetti V., Carenzi S., Premoli A., Debernardi-Venon W., et al. Viral load at the time of liver transplantation and risk of hepatitis B virus recurrence. Liver Transpl 11 (2005) 402-409
12. Lo C.M., Liu C.L., Lau G.K., Chan S.C., Ng I.O., and Fan S.T. Liver transplantation for chronic hepatitis B with lamivudine-resistant YMDD mutant using add-on adefovir dipivoxil plus lamivudine. Liver Transpl 11 (2005) 807-813
13. Roche B., Feray C., Gigou M., Roque-Afonso A.M., Arulnaden J.L., Delvart V., et al. HBV DNA persistence 10 years after liver transplantation despite successful anti-HBs passive immunoprophylaxis. Hepatology 38 (2003) 86-95
14. Terrault N.A., Zhou S., Combs C., Hahn J.A., Lake J.R., Roberts J.P., et al. Prophylaxis in liver transplant recipients using a fixed dosing schedule of hepatitis B immunoglobulins. Hepatology 24 (1996) 1327-1333
15. Grellier L., Mutimer D., Ahmed M., Brown D., Burroughs A.K., Rolles K., et al. Lamivudine prophylaxis against reinfection in liver transplantation for hepatitis B cirrhosis. Lancet 348 (1996) 1212-1215
16. Zheng S., Chen Y., Liang T., Lu A., Wang W., Shen Y., et al. Prevention of hepatitis B recurrence after liver transplantation using lamivudine or lamivudine combined with hepatitis B immunoglobulin prophylaxis. Liver Transpl 12 (2006) 253-258
17. Lo C.M., Cheung S.T., Lai C.L., Liu C.L., Ng I.O., Yuen M.F., et al. Liver transplantation in Asian patients with chronic hepatitis B using lamivudine prophylaxis. Ann Surg 233 (2001) 276-281
18. Dickson R.C., Terrault N.A., Ishitani M., Reddy K.R., Sheiner P., Luketic V., et al. Protective anti-body levels and dose requirements for IV 5% Nabi Hepatitis B immune globulin combined with lamivudine in liver transplantation for hepatitis B-induced end stage liver disease. Liver Transpl 12 (2006) 124-133
19. Sánchez-Fueyo A., Rimola A., Grande L., Costa J., Mas A., Navasa M., et al. Hepatitis B immunoglobulin discontinuation followed by hepatitis B virus vaccination: a new strategy in the prophylaxis of hepatitis B virus recurrence after liver transplantation. Hepatology 31 (2000) 496-501
20. Angelico M., Di Paolo D., Trinito M.O., Petrolati A., Araco A., Zazza S., et al. Failure of a reinforced triple course of hepatitis B vaccination in patients transplanted for HBV-related cirrhosis. Hepatology 35 (2002) 176-181
21. Bienzle U., Günther M., Neuhaus R., Vandepapeliere P., Vollmar J., Lun A., et al. Immunization with an adjuvant hepatitis B vaccine after liver transplantation for hepatitis B-related disease. Hepatology 38 (2003) 811-819
22. Dodson S.F., de Vera M.E., Bonham C.A., Geller D.A., Rakela J., and Fung J.J. Lamivudine after hepatitis B immune globulin is effective in preventing hepatitis B recurrence after liver transplantation. Liver Transplant 6 (2000) 434-439
23. Naoumov N.V., Lopes A.R., Burra P., Caccamo L., Iemmolo R.M., de Man R.A., et al. Randomized trial of lamivudine versus hepatitis B immunoglobulin for long-term prophylaxis of hepatitis B recurrence after liver transplantation. J Hepatol 34 (2001) 888-894
24. Buti M., Mas A., Prieto M., Casafont F., González A., Miras M., et al. Adherence to lamivudine after an early withdrawal of hepatitis B immune globulin plays an important role in the long-term prevention of hepatitis B virus recurrence. Tranplantation 84 (2007) 650-654
25. Neff G.W., O'brien C.B., Nery J., Shire N., Montalbano M., Ruiz P., et al. Outcomes in liver transplant recipients with hepatitis B virus: resistance and recurrence patterns from a large transplant center over the last decade. Liver Transpl 10 (2004) 1372-1378
26. Wong S.N., Chu C.J., Wai C.T., Howell T., Moore C., Fontana R.J., et al. Low risk of hepatitis B virus recurrence after withdrawal of long-term hepatitis B immunoglobulin in patients receiving maintenance nucleos(t)ide analogue therapy. Liver Transpl 13 (2007) 374-381